Day One Biopharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 142.18 million compared to USD 70.65 million a year ago. Basic loss per share from continuing operations was USD 2.17 compared to USD 4.62 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.27 USD | -2.43% | -3.63% | -9.11% |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
May. 20 | BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.11% | 1.16B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- DAWN Stock
- News Day One Biopharmaceuticals, Inc.
- Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022